The project TargetAMD was funded by the European Commission in the context of the Seventh Framework Programme classified to the topic health.
TargetAMD brought together an interdisciplinary team of outstanding scientists from 8 European countries. Five enterprises, three academic partners, five University Hospitals and Universities represented the international consortium of 13 partners.
The project was led by the University of Geneva, Prof. Gabriele Thumann, Dept. of Ophthalmology and assisted by professional EU project management of RWTH Aachen University, Ms. Maria Perdikomati-Dahmen.
The projects’ aim was to develop a transposon-based gene therapy for the exudative form of Age-related Macular Degeneration (AMD), and to translate the treatment into the First-In-Man clinical trial (phase Ib/ IIa) in Europe. The multifaceted consortium represented specialists offering a broad panel of experiences and knowledge in the pathology and treatment of AMD with key competences in the fields of genetic engineering, molecular and cell biology, in vivo modelling, ocular surgery, clinical studies, quality control and GMP-grade production.